AstraZeneca is looking to launch more than 15 new treatments in Japanover the next three years and increase its number of sales representatives from 1,000 to 1,500, according to the Nikkei Weekly. AstraZeneca KK currently sells Accolate (zafirlukast), Arimidex (anastrozole) and Losec/Prilosec (omeprazole).
R&D spending at AstraZeneca's Japanese unit is expected to rise 25% to 10 billion yen ($87.2 million), as the company looks to carry out more domestic clinical trials on treatments in the initial phase of development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze